Dear Editor, Adamzik et al. [1] reported that an elevated ratio of CD4 ? CD25 ?
Foxp3
? regulatory T cells (Tregs) to overall CD4
? cells in bronchoalveolar lavage (BAL) fluid portends a poor outcome for ARDS patients. A cellular biomarker able to provide prognostic information would be useful for ICU decision-making. However, we wish to highlight that the functional significance of alveolar Tregs remains undefined in ARDS.
Our group has shown in mouse models that Tregs-a lymphocyte subset that attenuates immune system activation and promotes repair in damaged tissues-resolve experimental lung injury via pro-repair effects on macrophage function and neutrophil efferocytosis [2] , epithelial regeneration [3] , and fibroproliferation [4] . It is unclear from the authors' data, obtained at a single time point, whether Tregs were actually pathogenic or if they accumulated as a pro-repair response to parenchymal damage. We hypothesize that severe lung inflammation, rather than the Tregs themselves, mediated the observed increase in mortality. A few findings call into question the study's conclusions: 
? status is insufficient to identify human Tregs and may include newly activated effector T cells. Other markers including CD3, CD127, and CD45 isoforms are usually advocated to increase specificity when analyzing human T lymphocyte populations [5] . A more specific Treg definition could have changed the conclusions of the study. Conflicts of interest This manuscript was prepared in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
